Medicaid Managed Care Open Enrollment Extended through Dec. 15
Current Suspected Overdose Deaths in Delaware for 2017: 225
The Delaware Division of Public Health (DPH) wishes to pass on this important announcement from the Centers for Disease Control and Prevention (CDC) regarding the use of Azithromycin for the treatment of Chlamydia and Gonorrhea.
Several media outlets have reported on a study that links azithromycin to sudden death. Azithromycin is a commonly used antibiotic, often prescribed to treat respiratory infections, ear infections, and sexually transmitted diseases (STDs).
As the public health agency [i.e. CDC] tasked with researching and developing STD treatment guidelines, we want to take this opportunity to point out that the findings from this study may not necessarily apply to patients who are treated with azithromycin for Chlamydia or gonorrhea. It is important to note that a five day regimen of azithromycin was studied and discussed in recent media reports -- not a single dose regimen as recommended for Chlamydia or dual therapy for gonorrhea.
Do not modify treatment regimens for patients receiving azithromycin for Chlamydia and gonorrhea based on recent media reports. CDC’s guidance for treating Chlamydia and gonorrhea with azithromycin remain as follows:
The Sexually Transmitted Diseases Treatment Guidelines, 2010 can be found in its entirety at http://www.cdc.gov/std/treatment/2010/. If you have questions or concerns, please contact 1-800-CDC-INFO.
You are receiving this message because you are a registered member of the Delaware Health Alert Network. If you are not a member and would like to subscribe, please register at https://healthalertde.org